Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aprea Therapeutics Inc
(NQ:
APRE
)
3.517
-0.003 (-0.09%)
Streaming Delayed Price
Updated: 3:54 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aprea Therapeutics Inc
< Previous
1
2
Next >
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Today 8:30 EDT
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
June 21, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Inc. (NASDAQ: APRE) Making Surprising Moves in Thursday Session
April 06, 2023
Via
Investor Brand Network
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 17, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 14, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 10, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 26, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 05, 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor)
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 06, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
January 30, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
January 04, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
October 24, 2023
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
October 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
August 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
August 10, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
June 14, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Present at BIO International Convention
May 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
May 15, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
May 08, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
March 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
March 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
March 07, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 01, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.